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PURPOSE. Pharmacologic modulation of wound healing after
glaucoma filtering surgery remains a major clinical challenge in
ophthalmology. Poly(ortho ester) (POE) is a bioerodible and
biocompatible viscous polymer potentially useful as a sus-
tained drug delivery system that allows the frequency of in-
traocular injections to be reduced. The purpose of this study
was to determine the efficacy of POE containing a precise
amount of 5-fluorouracil (5-FU) in an experimental model of
filtering surgery in the rabbit.
METHODS. Trabeculectomy was performed in pigmented rabbit
eyes. An ointmentlike formulation of POE containing 1% wt/wt
5-FU was injected subconjunctivally at the site of surgery,
during the procedure. Intraocular pressure (IOP), bleb persis-
tence, and ocular inflammatory reaction were monitored until
postoperative day 30. Quantitative analysis of 5-FU was per-
formed in the anterior chamber. Histologic analysis was used to
assess the appearance of the filtering fistula and the polymer’s
biocompatibility.
RESULTS. The decrease in IOP from baseline and the persistence
of the filtering bleb were significantly more marked in the
5-FU–treated eyes during postoperative days 9 through 28.
Corneal toxicity triggered by 5-FU was significantly lower in
the group that received 5-FU in POE compared with a 5-FU
tamponade. Histopathologic evaluation showed that POE was
well tolerated, and no fibrosis occurred in eyes treated with
POE containing 5-FU.
CONCLUSIONS. In this rabbit model of trabeculectomy, the for-
mulation based on POE and containing a precise amount of
5-FU reduced IOP and prolonged bleb persistence in a way
similar to the conventional method of a 5-FU tamponade, while
significantly reducing 5-FU toxicity. (Invest Ophthalmol Vis
Sci. 2001;42:695–700)
Glaucoma filtering surgery involves producing a filtrationfistula to allow controlled escape of aqueous humor from
the surgical trabeculectomy into the subconjunctival space.
The body’s natural tendency to heal, however, can seal the
surgical site and result in failure of the operation.1,2 The use of
drugs that interfere with early postoperative wound healing by
inhibiting fibroblast proliferation and preventing closure of the
filtration fistula has become increasingly important in improv-
ing the success rate of glaucoma filtering surgery in patients at
high risk of surgical failure. Drugs with proven efficacy include
5-fluorouracil (5-FU)3 and mitomycin C.4–7
The antimetabolite 5-Fu is a fluorinated pyrimidine analogue
that competitively inhibits thymidylate synthetase, resulting in
thymidine deficiency and decreased DNA synthesis. Currently,
5-FU is administered by frequent subconjunctival injections
away from the surgical site. Such frequent 5-FU injections are
inconvenient for the surgeon and uncomfortable for the pa-
tient. Furthermore, therapeutic drug levels are only transiently
achieved, necessitating frequent injections and administration
of large amounts of drug. Toxic effects on the surrounding
ocular tissues are a predictable consequence of this dosage
regimen. Toxicity on the conjunctival and corneal epithelium,
wound dehiscence, and wound leaks have been reported after
repeated subconjunctival administration of 5-FU.3 Topical in-
traoperative administration of 5-FU with a sponge soaked in a
concentrated drug solution has also been used and is associ-
ated with adverse side effects, some of which are vision threat-
ening.8 Another disadvantage of this mode of administration is
the high drug concentration to which the tissues are exposed
during the tamponade as well as the imprecision of the amount
of 5-FU delivered to the tissues.
These complications may be reduced by using subconjunc-
tivally implanted drug delivery systems that would provide a
localized and sustained release of antiproliferative drugs over
an extended period (approximately 2 weeks) and then would
disappear, leaving a patent fistula after glaucoma filtering sur-
gery. This 2-week period is critical with respect to inflamma-
tory and fibrotic reactions.9 Drug delivery systems investigated
to date include collagen implants,10,11 bioerodible poly-
mers,12–15 nonbioerodible polymers,16 liposomes,17 and mi-
crospheres.18
Poly(ortho esters) (POE) are a new family of hydropho-
bic, biocompatible,19,20 and bioerodible polymers possess-
ing particularly interesting characteristics. Biodegradability
represents a significant advantage over other drug delivery
systems, because there is no need to remove the device
surgically once all the drug has been released. Kinetics of
drug release from POE, as well as polymer degradation rate,
are almost constant, without any burst effect, and can be
controlled by factors such as polymer molecular weight and
the physicochemical properties of the incorporated sub-
stances.21,22 The viscous, ointmentlike consistency of the
polymeric material allows the incorporation of drugs into
the carrier by simple mixing at room temperature, without
the use of solvents. POE can be injected using a conven-
tional syringe with an appropriate needle, which is a signif-
icant advantage when compared with solid devices that
must be placed either with a trocar or through a more
complex surgical procedure. Moreover, the viscous proper-
ties of POE make its presence within the eye smooth and
nontraumatic, because it spreads in the space.
The purpose of this study was to evaluate a sustained drug
delivery system based on POE and 5-FU as an adjunct treatment
to filtering surgery in rabbits.
From the Department of 1Pharmaceutical Technology and Bio-
pharmaceutics and the Department of 3Pharmaceutical Analytical
Chemistry, School of Pharmacy, University of Geneva, Switzerland; and
the 2Department of Ophthalmology, Hoˆtel-Dieu Hospital, Paris, France.
Supported by Swiss National Science Foundation Grant
32.46795.96 and Fondation pour l’Avenir, France.
Submitted for publication June 9, 2000; revised November 20,
2000; accepted December 5, 2000.
Commercial relationships policy: N.
Corresponding author: Robert Gurny, Department of Pharmaceu-
tical Technology and Biopharmaceutics, School of Pharmacy, Univer-
sity of Geneva, 30 quai Ernest-Ansermet, CH-1211 Geneva 4, Switzer-
land. robert.gurny@pharm.unige.ch
Investigative Ophthalmology & Visual Science, March 2001, Vol. 42, No. 3
Copyright © Association for Research in Vision and Ophthalmology 695
MATERIALS AND METHODS
Polymer Synthesis
As described earlier,23 POE is synthesized by a transesterification reac-
tion between 1,2,6-hexanetriol and trimethyl orthoacetate (Aldrich
Chemie, Steinheim, Germany) under anhydrous and aseptic condi-
tions. POE is further purified by a precipitation procedure in methanol
to remove impurities such as residual monomers and oligomers.
The polymer was characterized by infrared spectroscopy, nuclear
magnetic resonance and size exclusion chromatography.22 The aver-
age molecular weight of the polymer used in this study is 9.3 kDa, with
a polydispersity of 1.4. POE is a viscous material, with Newtonian
behavior. It is transparent, with a refractive index of 1.47 and is gel-like
in appearance.
Preparation of the Formulations
Formulations were prepared under a laminar air-flow hood. The added
drug, 5-FU (Sigma, Buchs, Switzerland), had been g-sterilized at 2.0
MRad and homogeneously dispersed in the aseptically prepared semi-
solid polymer under aseptic conditions at a concentration of 1% wt/
wt.24 The viscous mixture was conditioned into a 1.0-ml syringe, each
sample being 200 ml (240 mg).
Animals
Pigmented Fauve de Bourgogne female rabbits weighing from 2 to 3
kg, 10 to 12 weeks of age, were used (Jean-Pierre Ravaut; Institut de la
Recherche Agronomique, Nouzilly, France), and experiments were
conducted in accordance with the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research. Six eyes were used in
each experimental group.
Filtering Surgery
General anesthesia was induced with intramuscular injection of 50
mg/kg ketamine and 15 mg/kg xylazine. With rabbits under local
anesthesia with oxybuprocaine 0.4% (Novesine; Ciba Vision, Basel,
Switzerland), a lid speculum was inserted to expose the globe. A
limbus-based conjunctival flap was reflected. Tenonectomy was per-
formed to expose the underlying sclera, followed by careful conjunc-
tival dissection anterior to the limbus. Hemostasis was carefully main-
tained with cautery. A half-thickness, limbal-based, 4 3 4-mm scleral
flap was made that extended just anterior to the limbus. At this point,
one group of rabbits received an intraoperative tamponade of 5-FU. A
4 3 1-mm dry section of a Weck-Cel sponge (Edward Weck, Research
Triangle Park, NC) was soaked in a 50-mg/ml 5-FU solution (Fluoro-
uracil; Teva, Mijdrecht, The Netherlands). The sponge was placed
between the conjunctiva and the sclera over the planned filtration site
for 5 minutes. The corneal epithelium was protected by applying a wet
sponge over the cornea. The treated area was thoroughly irrigated with
20 ml of balanced salt solution. A 3-mm limbal incision was made with
a 45° blade that entered the anterior chamber. A block of tissue
containing inner sclera, trabeculum and peripheral cornea, measuring
approximately 3 3 1 mm, was excised at the limbus. A peripheral
iridectomy was then performed. The scleral flap was approximated
with two 10-0 nylon sutures. The conjunctiva was repositioned and the
wound closed with 8-0 Vicryl suture (Ethicon, Piscataway, NJ) in a
continuous fashion. Just before the last step, a 0.9-mm needle (20-
gauge) was inserted in the subconjunctival space, and 200 ml of
polymer mixture was injected adjacent to the trabeculectomy. The
suture was closed tightly, and topical neomycin ophthalmic ointment
was applied.
Four different groups were tested (n 5 6): group I, eyes that
underwent trabeculectomy alone; group II, eyes that received 5-FU as
an intraoperative tamponade; group III, eyes that received POE alone;
and group IV, eyes that received POE containing 1% wt/wt 5-FU.
Clinical Observations
Slit-lamp observations were performed approximately every 2 days for
30 days after surgery to assess the filtering bleb status and the overall
inflammatory state of the eye. Intraocular pressure (IOP) was measured
at the same time intervals using Goldmann applanation tonometry,
with rabbits under local anesthesia, and was compared with the pre-
operative IOP.
Statistical analysis was performed to compare experimental data
with data from control eyes, using a nonparametric Mann–Whitney
test. The following variables were analyzed: IOP, time to bleb failure,
conjunctival hyperemia, and corneal edema. P , 0.05 was considered
significant.
Quantitative Determination of 5-FU
Concentrations of 5-FU were determined by liquid chromatography
(LC) using a high-performance liquid chromatography (HPLC) system
(LC module I plus; Waters, Milford, MA), consisting of a power line
controller pump (model 600E) an autoinjector (715 Ultra WISPTM), a
tunable absorbance UV detector set at 268 nm, and a software inte-
grator (Millennium) all from Waters. Separation was performed with a
C18 HPLC column (Nucleosil 100-5; Macherey Nagel, Du¨ren, Germany;
250 3 4.0 mm; internal diameter, 5 mm). The mobile phase consisted
of ammonium phosphate buffer (50 mM; pH 6.0) delivered at 1.0
ml/min. Before use, the mobile phase was filtered through a 0.45-mm
membrane filter (Millipore, Molsheim, France) and degassed 10 min-
utes by sonication.
At postoperative days 1, 2, 5, 7, and 14, a paracentesis was made
with rabbits under local anesthesia, and 100 ml of aqueous humor was
collected for quantitative analysis. Samples and quantitative standards
were homogenized and directly injected into the HPLC system, with an
injection volume of 20 ml.
Histologic Analysis
Rabbits were killed at different time points ranging from 5 to 30 days
after surgery by intracardiac injection of a lethal dose of pentobarbital,
and their eyes were enucleated and fixed to be studied histologically
by conventional optical microscopy. Anteroposterior sections were
stained with hematoxylin-eosin to examine the conjunctiva, the irido-
corneal angle, and the appearance of the site of the bleb. Every sample




Clinical Appearance of the Eyes. Eyes were observed
clinically for 30 days with special attention to conjunctival
hyperemia and corneal edema. Results are summarized in Fig-
ure 1. Conjunctival hyperemia was scored according to a mod-
ified Draize test19: grade 0, normal vessels; grade 1, definitely
injected vessels; grade 2, diffuse crimson red, individual vessels
not easily discernible; and grade 3, diffuse beefy red. Corneal
edema was scored as follows: grade 0, normal cornea; grade 1,
slight corneal edema present at the surgical site; grade 2,
diffuse corneal edema extending to half the surface of the
cornea; and grade 3, opaque cornea with neovascularization.
Trabeculectomy triggered slight hyperemia of the conjunc-
tiva that resolved after approximately 1 week. When 5-FU was
applied as a tamponade, no significant increase of the hyper-
emia occurred. Hyperemia triggered by the presence of POE,
with or without 5-FU (groups III and IV), had a score approx-
imately 0.25 higher than in group I, with a significant differ-
ence at day 5. Eventually, hyperemia disappeared as the poly-
mer degraded, by 2 weeks after surgery.19
At the site of surgery, trabeculectomy also triggered revers-
ible edema of the cornea, which reached its apex at day 5. The
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presence of POE triggered edema of the same intensity, which
was also reversible. In contrast, 5-FU applied during surgery as
a tamponade triggered more severe edema, extending to half
the cornea (Fig. 2, II). The frequency and the severity of
corneal edema in the 5-FU tamponade group was significantly
higher than in any other group. Superficial punctuate keratitis
occurred in two eyes. The group that received POE15-FU also
showed some edema, but it remained localized at the surgical
site and was not significantly different from that in the control
groups (Fig. 2, IV).
POE could be observed at the subconjunctival site for 12
days, but the incorporation of the acidic 5-FU into the POE
active formulation reduced its presence to 10 days because of
accelerated, acid-catalyzed, degradation.21,22 After that time,
POE seemed to disappear from the eye after bioresorption. It is
possible that some POE may still have been present under the
conjunctiva, but not visibly so, with the viscous POE spreading
in the subconjunctival space. Moreover, it was sometimes
difficult to distinguish a POE bubble from the filtering bleb.
Bleb Appearance and Survival Curves. In group I (con-
trol eyes that underwent trabeculectomy alone), all blebs were
elevated and typically had sharply demarcated edges a few days
after surgery. Fifty percent of blebs had collapsed by 9 days and
100% by 19 days. In group II (eyes that received an intraoper-
ative 5-FU tamponade), the blebs were significantly more per-
sistent, lasting from day 12 until the end of the experiment
(day 29). Group III, which received POE alone, showed de-
layed persistence of the bleb compared with group I (Fig. 2, I
and III), but eventually all blebs failed. All blebs in group IV
(POE containing 5-FU) survived until postoperative day 19, and
83% survived after 1 month. There were no significant differ-
ences between group IV and group II. Bleb survival curves for
the four groups are displayed in Figure 3.
Intraocular Pressure. In group I, the mean IOP returned
to preoperative levels by day 9 (Fig. 4). In eyes that received
polymer alone (group III), IOP also returned to baseline values,
but with some delay. There was no statistical difference be-
tween these two control groups at any time.
Eyes treated with 5-FU either as a tamponade (group II) or
incorporated in POE (group IV), had significantly lower IOP
than control groups from day 9 until the end of the experi-
FIGURE 1. Evaluation of conjunctival hyperemia and corneal edema.
Group I (f), group II ( ), group III ( ), and group IV (M). n 5 6,
mean 6 SD. *Significant difference from group I (P , 0.05).
FIGURE 2. Eye status in each group
at postoperative day 7.
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ment. However, no statistical difference was found between
these two 5-FU groups (Fig. 5).
Quantitative Determination of 5-FU
The quantitative determination of 5-FU concentration in the
aqueous humor is particularly important to ensure that the
levels reached are not toxic to the corneal endothelium. Cor-
neal toxicity includes epithelial defects, corneal opacification,
and vascularization.
In all eyes that received POE15-FU, quantitative determina-
tion of 5-FU in the aqueous humor showed detectable amounts
of 5-FU (below 0.5 mg/ml) for 2 weeks, which shows that POE
was still present in the subconjunctival space for that period
and released 5-FU in a continuous fashion. In particular, no
burst release of 5-FU was observed in the early postoperative
period, according to observations for in vitro 5-FU release.22
Thus, at each time point, a minimal amount of 5-FU was
present in the anterior chamber, corresponding at least to 3
orders of magnitude below the threshold concentration for
5-FU toxicity to the corneal endothelium (1–10 mg/ml) re-
ported by Mannis et al.25
5-Fluorouracil was not quantified in the anterior chamber of
eyes that received an intraoperative tamponade for several
reasons: 5-FU is applied and rinsed off before opening the
anterior chamber, and therefore no 5-FU should penetrate into
the eye; 5-FU soaks the surrounding tissues and does not
diffuse into the anterior chamber; moreover the flux direction
is opposite to the direction of the possible 5-FU intracameral
penetration; and last, in all the published literature concerning
5-FU intraoperative tamponade,4,6,8,26,27 none of the authors
ever measured the 5-FU concentrations in the anterior cham-
ber.
Histology
In control animals killed at 5 days after surgery, a bleb was
present, and the trabeculectomy was patent. Some inflamma-
tory cell (polymorphonuclear cells) infiltration was observed
around the margins of the scleral flap. The edges of the iris
around the iridectomy had partially prolapsed into the fistula in
some specimens, although they did not completely block it. No
evidence of any conjunctival filtration could be seen.
Bleb failure occurred at 10 days in eyes that underwent
trabeculectomy alone (group I). Eyes showed evidence of in-
flammatory cell infiltration and fibrovascular tissue at the sur-
gical site. The trabeculectomy and bleb closed due to bulk
filling by granulation tissue and fibroblasts.
Until the end of the experiment, eyes that received 5-FU,
either as a tamponade or incorporated in POE, showed no signs
of fibrosis of the filtration fistula. The scleral flap margins were
absent from any fibrotic subconjunctival fibroblasts (Fig. 6).
The conjunctival filtration was efficient, visible as a small cavity
surrounded by fibrin and cells. Some slight modifications of the
iris were observed, notably pigment redistribution. These mod-
ifications of the uvea were more marked in the 5-FU tampon-
ade group in which significant pigment alterations and pig-
ment migration into the external tunica were observed.
Eyes were also observed to detect any inflammatory reac-
tion triggered by POE. A transient acute inflammatory reaction
was observed in the subconjunctival space, with granulated
neutrophils around POE by day 5, as previously described.19
This inflammatory reaction was resolved within 2 weeks, with
neither recurrence nor encapsulation of the biomaterial. In
some eyes, giant multinucleated cells were found around cav-
ities that were empty or filled with some grayish material,
probably POE. No histologic evidence of chronic inflammation
FIGURE 3. A Kaplan–Meier graph of the duration of blebs in rabbits:
group I (solid line), group II (long-short dashes), group III (long
dashes), and group IV (short dashes). n 5 6; mean 6 SD.
FIGURE 4. Postoperative IOP of rabbits that received POE with 1%
5-FU versus control animals. Group I (solid), group III (long dashes),
and group IV (short dashes). n 5 6; mean 6 SD. *Significant difference
from group I (P , 0.05).
FIGURE 5. Postoperative IOP of rabbits having received POE with 1%
5-FU versus 5-FU as a tamponade: group II (long-short dashes) and
group IV (short dashes). n 5 6, mean 6 SD.
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was found after 4 weeks after surgery. These results confirm
the previously described biocompatibility of POE.19,20
DISCUSSION
The surgical technique, a half-thickness trabeculectomy, used
in this study produced a lowering of the IOP, which returned
to normal values within 7 to 10 days after surgery, as observed
in the control groups. Closure and fibrosis of the trabeculec-
tomy followed the general pattern of acute inflammation and
repair. Fibrosis can be equated to the disappearance of the
filtering bleb, as well as to the return to normal, preoperative
IOP values. When POE alone was injected subconjunctivally,
IOP rose after approximately 15 days. The delay could be
explained by the physical presence of POE at the surgical site,
which may have delayed the occlusion of the fistula. Moreover,
the existence of different chemical entities at the trabeculec-
tomy site (i.e., the polymer and its degradation by-products)
may have altered the inflammatory reaction.
Intraoperative 5-FU had a marked effect on IOP that lasted
longer than is reported in the literature. Khaw et al.26 reported
a significant difference from the control from day 5 to day 18
for the same dosage regimen in rabbits. In our model, filtering
blebs lasted at least 1 month. However, intraoperative applica-
tion of 5-FU triggered severe complications, such as corneal
edema and epithelial defects.
The administration of POE containing 5-FU promoted the
success of glaucoma filtering surgery in rabbit eyes. Eyes that
received POE and 5-FU after trabeculectomy had lower IOP for
at least 1 month, and they showed filtration blebs and patent
fistulas, as supported by the histopathologic findings. This
improvement in the duration of lowered IOP in the experimen-
tal eyes was due to the slow and continuous release of 5-FU
from the polymeric matrix, inducing facilitated outflow. In
both groups that received 5-FU, no abnormal morphologic
changes were seen in the ciliary body epithelium and trabec-
ular meshwork when compared by light microscopy with
control eyes. When incorporated in POE, 5-FU also appeared to
trigger less toxic reactions, such as corneal edema than when
administered during surgery.27 The slow release of 5-FU from
POE prevented the focal attainment of high and toxic drug
levels. Clinical observations showed that eyes that received
POE with 5-FU had reactions similar to those in control eyes.
There was some conjunctival hyperemia and corneal edema,
but the intensity was comparable to that in control eyes.
POE is a new biomaterial with potential as a controlled
release system for drugs as an adjunct treatment in glaucoma
filtering surgery. Sustained release of an antiproliferative drug
such as 5-FU from a POE carrier means that only one subcon-
junctival injection must be performed at the time of surgery
and enables a precise and small amount of drug to be admin-
istered. In contrast, during an intraoperative tamponade, tis-
sues are exposed to a high concentration of antiproliferative
drug that is potentially toxic to the corneal epithelium,28 and
they are soaked with a very variable, uncontrolled, and unpre-
dictable amount of drug that diffuses rapidly from the sponge.
Moreover, the 5-FU solution is basic (pH 9.0) to increase drug
solubility, which can also trigger a more acute inflammatory
response. We showed that both techniques—that is, the incor-
poration of a low amount of 5-FU (2.4 mg) in POE or an
intraoperative tamponade with a 50-mg/ml 5-FU solution—
showed comparable results in IOP and bleb persistence. The
incorporation of 5-FU in POE also reduced the toxicity of the
drug, because lower amounts had to be used.
Although the results described in previous studies with
other biomaterials are very encouraging,13 our system provides
several additional intrinsic advantages. Regarding physical
properties, the viscous consistency of POE makes it slightly
traumatic to ocular structures, compared with solid devices.13
After injection, POE spreads under the conjunctiva and as-
sumes the curve of the ocular globe. Concerning chemical
characteristics, the hydrophobic backbone of the polymer al-
lows surface erosion and thus a linear and almost constant
release of drugs.22 Burst release, which is often encountered
with poly(DL lactic-co-glycolic acid) PLGA-based systems,29 is
avoided. The burst release of a drug such as 5-FU with its
associated toxicity could have dramatic effects on tissue toler-
ance. Also, POE has shown excellent biocompatibility in sev-
eral parts of the eye,20 notably under the conjunctiva.19 Com-
pared with reported results with collagen11 or PLGA,30 POE is
better tolerated. Another advantage is that POE does not be-
come encapsulated, because it is progressively resorbed in
approximately 2 weeks, in contrast to PLGA-based systems,
which degrade more slowly than the drug is released and thus
present a risk of encapsulation.13
All animal models of glaucoma filtering surgery have advan-
tages and disadvantages. This study demonstrates a consistent
and predictable response of the tissues in the normal rabbit,
with the trabeculectomy closing and the bleb collapsing within
a short and convenient time period. The overall pattern of
wound healing is similar to scars found in humans,31 although
more rapid. It has also been reported32 that a significant re-
duction in IOP may occur, even in the absence of a patent
trabeculectomy, and bleb function is thus a more reliable index
to assess the fistula’s efficacy. Also, there are numerous ana-
tomic differences between rabbit and human eyes. Notably,
eyeball motion is more frequent in man, eyelid pressure is
higher, and the iris is less prone to incarcerate the channel in
rabbits than in man, so the potential for the mixture to ooze
into the anterior chamber is higher in patients. However, we
have seen that the concentrations obtained in the rabbit ante-
FIGURE 6. Histologic section through the iridocorneal angle after tra-
beculectomy and subconjunctival injection of 200 ml POE15-FU.
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rior chamber after the administration of the POE 5-FU for-
mulation were 103 times lower than reported toxic con-
centrations. As a consequence, it is improbable that 5-FU
concentrations in the human anterior chamber would increase
3 orders of magnitude; however, this should be investigated.
This newly developed drug delivery system based on bio-
erodible POE has potential for clinical applications in glaucoma
filtering surgery in patients who are at high risk of failed
surgery. Scarring at the filtration site can be inhibited by a
localized and sustained release of a very small yet efficient
amount of the antifibroblastic agent 5-FU, therefore avoiding
the need for frequent subconjunctival injections and decreas-
ing toxic ocular side effects caused by intraoperative topical
administration of higher amounts of drug. POE combines the
advantage of a hydrophobic polymer, allowing a slow release
of the hydrophilic drug 5-FU for 2 weeks, with a relatively fast
biodegradability. Its proven biocompatibility makes it a bioma-
terial of choice to deliver drugs in a sustained, controllable
way. A study over 6 months is currently under way to assess a
long-term follow-up.
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